Results from a Randomized Study of REVLIMID(R) (Lenalidomide) and Rituximab (R ... MarketWatch (press release) Celgene International Sarl, a subsidiary of Celgene Corporation (NASDAQ:CELG) , today announced results from a randomized study comparing REVLIMID(R) (lenalidomide) plus rituximab to lenalidomide monotherapy in previously treated patients with ... Results from a Randomized Study of REVLIMID® (Lenalidomide) and Rituximab (R2 ... Celgene Reveals Results From Revlimid Study For Recurrent Follicular Lymphoma |
